

HARRY FISCH, M.D.

tel: [REDACTED]
fax: [REDACTED]

FACSIMILE TRANSMISSION

Date: 8/9/16

PLEASE DELIVER ATTACHED MESSAGE

TO: Jeffrey Epstein

FAX #: _____

TEL #: _____

Regarding: _____

Number of pages (including cover page): _____

Remarks: _____

7/26/16 Jeffrey Epstein

- Agis Belam, 7 months

2/1/16 - fern cult - neg

circled:
 conical
 negative
 negative

Typhoid - 9/10

circled:
 + (H. pylori)
 - urethral
 discharge

UA, (+) → NK (NO ASC)

1 week to #4

clo/amin Treas (7 ug Augu x 20x)

circled:
 - / had
 was edm
 2007 + more
 1/4 media

2/10 + black

no stool clo + stream (figue OK)

same in colon, 1st lobes small (5 of 17) + why was
 w/ Antibiotics (Papan) current

A goal in the treatment of symptomatic BPH...

LOWER THEIR SCORE in

FLOMAX frequently provides symptom relief in lowering the AUA Symptom Score of younger and older men with BPH

As with other alpha-adrenergic blocking agents, there is a potential risk of dizziness. Patients beginning treatment with FLOMAX should be cautioned to avoid situations where dizziness could result should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
 References: 1. Sussman P, O'Leary MP, Davida G. Beta efficacy of tamsulosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J App Res. 2005; 237-245. 2. Chapple CR, Soori F, Thind P, et al, on behalf of the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). Eur Urol. 1997;32:462-470.



Tues - 57.4 pm
91 vancouver
TAN

Medd - 125a wood

Address -
at 8 pm to be seen to be
ministry D 4 weeks

Mr. Thepue 2⁰ minutes

Mc # D -

- Rain back 2⁰ dex unit
not 5 lenses

- Ash 2⁰

- second demand but not

- staying 4 weeks

DOCTOR

FISCH, HARRY
HARRY FISCH, M.D.
[REDACTED]
New York, NY 10028
Acct #: (C1720-1) S1
P: [REDACTED]

PATIENT

EPSTEIN, JEFFREY
DOB: 01/20/1953 Age: 63 Y Sex: M
Address: 9 E 71ST STREET
NEW YORK, NY 10021
P: (2) [REDACTED]

SAMPLE

Specimen ID: 105819158
Date Of Report: 07/23/2016
Date Collected: 07/20/2016
Time Collected: 08:52
Date Received: 07/20/2016
Time Received: 23:20
North America Eastern Time

CLINICAL REPORT

Clinical Abnormalities Summary: (May not contain all abnormal results; narrative results may not have abnormal flags. Please review entire report.)

Creatinine	0.62 LO	BUN/Creat Ratio	33.9 HI	ALT	42 HI
Cholesterol	210 HI	Triglycerides	950 HI	HDL CHOL., DIRECT	28 LO
HDL as % of Cholesterol	13	Chol/HDL Ratio	7.5		
MCHC	35.2 HI				
Hemoglobin A1c	5.9 HI				

NON FASTING

CHEMISTRY

Test	Result	Reference	Units	Previous Result	Date
Total Protein	7.0	5.9-8.4	g/dL	6.7	01/27/2016
Albumin	4.7	3.5-5.2	g/dL	4.2	01/27/2016
Globulin	2.3	1.7-3.7	g/dL	2.5	01/27/2016
A/G Ratio	2.0	1.1-2.9		1.7	01/27/2016
Glucose	93	70-99	mg/dL	99	01/27/2016
Sodium	140	135-147	mmol/L	141	01/27/2016
Potassium	4.6	3.5-5.5	mmol/L	4.2	01/27/2016
Chloride	97	96-108	mmol/L	102	01/27/2016
CO2	24	22-29	mmol/L	26	01/27/2016
BUN	21	8-23	mg/dL	22	01/27/2016
Creatinine	0.62 LO	0.80-1.30	mg/dL	1.11	01/27/2016
e-GFR	106	>or=60	mL/min	70	01/27/2016
e-GFR, African American	123	>or=60	mL/min	81	01/27/2016
BUN/Creat Ratio	33.9 HI	10.0-28.0		19.8	01/27/2016
Calcium	9.8	8.6-10.4	mg/dL	9.8	01/27/2016
Uric Acid	7.4	3.4-8.5	mg/dL	7.5	01/27/2016
Iron	96	45-160	ug/dL	75	01/27/2016
Bilirubin, Total	0.6	<1.2	mg/dL	0.5	01/27/2016
LD	206	135-225	U/L	171	01/27/2016
Alk Phos	70	40-156	U/L	43	01/27/2016
AST	32	<40	U/L	29	01/27/2016
Phosphorus	3.0	2.7-4.5	mg/dL	3.4	01/27/2016
ALT	42 HI	<41	U/L	29	01/27/2016
GGTP	19	10-71	U/L	18	01/27/2016

CARDIOVASCULAR/LIPIDS

Test	Result	Reference	Units	Previous Result	Date
Cholesterol	210 HI	<200	mg/dL	143	01/27/2016
Triglycerides	950 HI	<150	mg/dL	459 HI	01/27/2016
NOTE: The result for Triglycerides has been confirmed by repeat analysis.					
HDL CHOL., DIRECT	28 LO	>40	mg/dL	24 LO	01/27/2016
HDL as % of Cholesterol	13	>14	%	17	01/27/2016
Evaluation: ABOVE AVG.(MODERATE RISK)					
Chol/HDL Ratio	7.5	<7.4		6.0	01/27/2016

D
O
C
T
O
R

FISCH, HARRY
HARRY FISCH, M.D.
New York, NY 10028
Acct #: (C1720-1) S1
P: [REDACTED]

P
A
T
I
E
N
T

EPSTEIN, JEFFREY
DOB:01/20/1953 Age:63 Y Sex:M
Address:9 E 71ST STREET
NEW YORK, NY 10021
P: ([REDACTED]) [REDACTED]

S
A
M
P
L
E

Specimen ID: 105819158
Date Of Report: 07/23/2016
Date Collected: 07/20/2016
Time Collected: 08:52
Date Received: 07/20/2016
Time Received: 23:20

North America Eastern Time

CLINICAL REPORT

Test	Result	Abnormal	Reference	Units	Previous Result	Date
Evaluation: ABOVE AVG.(MODERATE RISK)						
LDL/HDL Ratio	Can't Calc		<3.56		Can't Calc	01/27/2016
LDL Cholesterol	Can't Calc		<100	mg/dL	Can't Calc	01/27/2016
NOTE: Unable to calculate LDL due to a Triglyceride level of greater than 400 mg/dL.						
VLDL, CALCULATED	Can't Calc		7-32	mg/dL	Can't Calc	01/27/2016

Can't Calc: One or more components was outside the measurable range. We are unable to calculate.

HEMATOLOGY

Test	Result	Abnormal	Reference	Units	Previous Result	Date
WBC	7.79		3.66-11.99	x10(3)/uL	7.12	01/27/2016
RBC	5.18		4.20-5.90	x10(6)/uL	4.96	01/27/2016
HGB	15.4		12.3-17.0	gm/dL	14.3	01/27/2016
HCT	43.8		39.3-52.5	%	41.3	01/27/2016
MCV	84.6		80.0-100.0	fL	83.3	01/27/2016
MCH	29.7		25.0-34.1	pg	28.8	01/27/2016
MCHC		35.2 HI	29.0-35.0	gm/dL	34.6	01/27/2016
RDW	14.8		10.9-16.9	%	13.9	01/27/2016
POLYS	45.8		36.0-78.0	%	49.2	01/27/2016
LYMPHS	39.0		12.0-48.0	%	36.2	01/27/2016
MONOS	8.9		0.0-13.0	%	7.6	01/27/2016
EOS	5.4		0.0-8.0	%	6.5	01/27/2016
BASOS	0.6		0.0-2.0	%	0.4	01/27/2016
IMMATURE GRANULOCYTES	0.0		0.0-1.6	%	0.1	01/27/2016
PLATELET COUNT	281		144-400	x10(3)/uL	222	01/27/2016
MPV	8.9		8.2-11.9	fL	9.5	01/27/2016
NOTE: New reference ranges for WBC and Absolute counts are effective 4/25/2016.						
PT	TNP		9.1-11.9	sec	10.1	01/27/2016
Test Not Performed: Specimen REJECTED for testing due to GROSS LIPEMIA.						
INTR.NORM.RATIO(INR)	TNP		2.00-3.00		0.97 LO	01/27/2016
PTT	TNP		23.6-31.6	sec	26.5	01/27/2016

URINALYSIS

Test	Result	Abnormal	Reference	Units	Previous Result	Date
Color	YELLOW		YELLOW, STRAW, AMBER			
Character	CLEAR		CLEAR			
Specific Gravity Ur	1.025		1.003 - 1.030			
pH Urine	6.5		5.0 - 8.0			
Protein, Urine	NEGATIVE		NEGATIVE			
Glucose, Urine	NEGATIVE		NEGATIVE			
Ketone, Urine	NEGATIVE		NEGATIVE			
Urobilinogen Urine	0.2		0.2 - 1.0	mg/dL		

DOCTOR

FISCH, HARRY
HARRY FISCH, M.D.
New York, NY 10028
Acct #: (C1720-1) S1
P: [REDACTED]

PATIENT

EPSTEIN, JEFFREY
DOB:01/20/1953 Age:63 Y Sex:M
Address:9 E 71ST STREET
NEW YORK, NY 10021
P: (212) [REDACTED]

SAMPLE

Specimen ID: 105819158
Date Of Report: 07/23/2016
Date Collected: 07/20/2016
Time Collected: 08:52
Date Received: 07/20/2016
Time Received: 23:20
North America Eastern Time

CLINICAL REPORT

Test	Result	Reference	Units	Reference Range	Date
Bilirubin, Urine	NEGATIVE				
Blood, Urine	NEGATIVE				
Nitrites Urine	NEGATIVE				
Leukocyte Esterase	NEGATIVE				
Crystals Urine	NONE				
Crystal Amt. Urine	NONE				
WBC, Urine	0-4		PER HPF		
RBC, Urine	NONE SEEN		PER HPF		
Epithelial Cells, Ur	NONE		FEW		
Cast, Hyaline, Urine	0-4		PER LPF		
Cast, Granular, Ur	NONE SEEN		PER LPF		
Cast, RBC, Urine	NONE SEEN		PER LPF		
Bacteria, Urine	NONE		FEW		

MICROBIOLOGY

Test	Result	Reference	Units	Reference Range	Date
CULTURE, URINE	NO GROWTH				
SITE: URINE					

MISCELLANEOUS

Test	Result	Reference	Units	Reference Range	Date
Hemoglobin A1c	5.9 HI	<5.7	%	6.0 HI	01/27/2016

HEMOGLOBIN A1c AND eAG REFERENCE RANGES

A1c(%)	DIABETES CATEGORY*
<5.7	Normal (non-diabetic)
5.7-6.4	Increased risk of diabetes
=>6.5	Consistent with diabetes
A1c(%)	eAG(ESTIMATED AVERAGE PLASMA GLUCOSE)(mg/dL)
6	126
7	154
8	183
9	212
10	240
11	269
12	298

*recommended ranges-American Diabetes Association(2010)

NOTE: Hemolysis, rare hemoglobin variants and thalassemia major may affect glycemic results.

Test	Result	Reference	Units	Reference Range	Date
TSH	TNP	0.178-4.530	uIU/mL	1.790	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.					
Thyroxine(T4)	TNP	4.9-12.9	ug/dL	6.3	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.					

DOCTOR
FISCH, HARRY
HARRY FISCH, M.D.
New York, NY 10028
Acct #: (C1720-1) S1
P: [REDACTED]

PATIENT
EPSTEIN, JEFFREY
DOB:01/20/1953 Age:63 Y Sex:M
Address:9 E 71ST STREET
NEW YORK, NY 10021
P: ([REDACTED]) [REDACTED]

SAMPLE
Specimen ID: 105819158
Date Of Report: 07/23/2016
Date Collected: 07/20/2016
Time Collected: 08:52
Date Received: 07/20/2016
Time Received: 23:20
North America Eastern Time

CLINICAL REPORT

Test	Result	Abnormal	Reference	Units	Previous Result	Date
hemolysis.						
T3 Uptake(T3U)	TNP		24.3-39.0	%	29.3	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
THYROXINE, FREE(FT4)	TNP		0.80-1.73	ng/dL	0.93	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
FREE T4 INDEX	TNP		1.5-3.8		1.8	01/27/2016
T3(THYRONINE), TOTAL	TNP		72-180	ng/dL	127	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
PSA Total	TNP		<4.00	ng/mL	0.76	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
NOTE: The PSA assay should not be the only test used for diagnostic purposes. Additional evaluation using DRE, ultrasound, TUR or similar procedures may be used for this purpose. Predictions of disease recurrence should not be based solely upon values obtained from serial PSA values obtained on the patient.						
NOTE: Values obtained with different assay methods or kits cannot be used interchangeably.						
NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.						
ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics)						
PSA, FREE	TNP		Not Estab.	ng/mL	0.33	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
NOTE: Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably.						
ASSAY INFORMATION: Method Electrochemiluminescence Immunoassay (Roche Diagnostics).						
% FREE PSA	TNP		See Below	%	47	01/27/2016
FREE PSA RISK ASSESSMENT						
The probability of prostate cancer for men with non-suspicious DRE results, by age group, using PSA values between 4.000 and 10.000 ng/mL and percent FREE PSA values is summarized in the table below:						

D
O
C
T
O
R

FISCH, HARRY
HARRY FISCH, M.D.
New York, NY 10028
Acct #: (C1720-1) S1
P: [REDACTED]

P
A
T
I
E
N
T

EPSTEIN, JEFFREY
DOB: 01/20/1953 Age: 63 Y Sex: M
Address: 9 E 71ST STREET
NEW YORK, NY 10021
P: ([REDACTED]) [REDACTED]

S
A
M
P
L
E

Specimen ID: 105819158
Date Of Report: 07/23/2016
Date Collected: 07/20/2016
Time Collected: 08:52
Date Received: 07/20/2016
Time Received: 23:20
North America Eastern Time

CLINICAL REPORT

Test	Result	Abnormal	Reference	Units	Previous Result	Date
PROBABILITY OF CANCER*						
%free PSA	(50-59 yrs)	(60-69 yrs)	(≥70 yrs)			
<or=10	49.2%	57.5%	64.5%			
11-18	26.9%	33.9%	40.8%			
19-25	18.3%	23.9%	29.7%			
>25	9.1%	12.2%	15.8%			
*probability of finding prostate cancer by needle biopsy						
NOTE: Calculation of percent FREE PSA may not be possible when the value for TOTAL PSA is in the low normal range. These guidelines are for assays performed using the Roche E602 immunoassay system.(8/2015;V8.0)						
TESTOSTERONE, TOT., S.	TNP		193.0-740.0	ng/dL	296.0	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
TESTOSTERONE, BIOAVAIL.	TNP		72.0-460.0	ng/dL	183.8	01/27/2016
SEX HORM.BIND.GLOB.	TNP		10-57	nmol/L	18	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
FREE TESTOSTERONE	TNP		30.00-150.00	pg/mL	80.18	01/27/2016
LH	TNP		1.7-8.6	mIU/mL	6.8	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
FSH	TNP		1.5-12.4	mIU/mL	6.8	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
PROLACTIN, SERUM	TNP		4.0-15.2	ng/mL	3.0 LO	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
ESTRADIOL	TNP		7.02-49.06	pg/mL	48.93	01/27/2016
Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis.						
FIBRINOGEN	TNP		176-441	mg/dL	276	01/27/2016
DIHYDROTESTOSTERONE(7)	148.0		106-719	pg/mL	278.0	01/27/2016
Reference Intervals for Males age 20 years and above: 106.0-719.0 pg/mL Analysis by High Performance Liquid Chromatography/ TandemMass Spectrometry (LC-MS/MS)						
(7) Performed by: National Medical Lab 2300 Stratford Ave. Willow Grove, PA 19090						